Company: STAA
Filing Date: 2025-10-09
Form Type: DFAN14A
Source: 0001213900-25-097833
Chunk: 19

Company: STAAR SURGICAL CO
Filing Date: 2025-10-09
Form: DFAN14A
Chunk 19
---
,
and injector systems.

ICL adoption has surged as patients seek reversible,
non-LASIK alternatives, though STAAR’s exposure to China, where sales plunged amid distributor destocking and weak consumer spending,
has been its Achilles’ heel. Broadwood argues the slump is temporary; STAAR says the market is nearing saturation.

<div align='center'>Exhibit 3-3</div>

The company’s appeal lies in a 30-year safety
record and growing U.S. adoption since the FDA approved EVO ICL in 2022. Critics of the Alcon deal say those advantages make the $28 sale
price particularly hard to justify.

Some investors view the STAAR dispute as part
of a broader pattern of aggressive consolidation by Alcon, which has engaged in six acquisitions or major investments over the past year.
Earlier this year, the Swiss eye-care giant faced litigation over its control of Aurion Biotech, where investors allege Alcon, through
the help of former STAAR CEO Thomas Frinzi, engineered a board deadlock to block an IPO and later acquired control at a discount.

To critics, STAAR fits a similar narrative: a
dominant player neutralizing a disruptive rival before its technology can erode market share. To supporters, STAAR faces higher odds of
failure standalone than it does with the support of a key industry player like Alcon, and investors get to benefit from the cash-in rather
than facing saturation risks.

Why it matters

If the merger passes, it will cement Alcon’s
dominance in ophthalmic lenses and deliver STAAR shareholders an immediate cash exit. If it fails, STAAR’s valuation could drop
in the short term, but Broadwood and its allies argue the company can recover, cut costs, and pursue a new, transparent sale process “from
a position of strength.”

As ISS’s recommendation and the October
23 vote approach, STAAR’s future and the credibility of its board hang on the outcome.

<div align='center'>Exhibit 3-4</div>

Exhibit 4

Defender Capital Opposes STAAR Surgical’s Proposed Sale to Alcon

CHARLOTTE, N.C., Oct. 7, 2025 /PRNewswire/ -- Defender
Capital (“Defender” or “we”), a long-term shareholder of STAAR Surgical Company (“STAAR” or the “Company”)
(NASDAQ: STAA) owning approximately 1.5% of the Company’s outstanding common stock, today issued the